Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution

D'Eredità, G; Giardina, C; Martellotta, M; T, Natale; Ferrarese, Filippo

doi:10.1016/s0959-8049(00)00435-4

Cited by 156 publications

(85 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Diagnosis of the specimens was made according to the World Health Organization (WHO) classification of the tumors. The malignant cases graded according to Nottingham Prognostic Index (NPI) [14]. All cases were asked to freely volunteer to the study and informed written consents were gathered prior to their inclusion in the study according to the guidance of Scientific Research Ethics Committee (IORG#: IORG0008812).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Immunohistochemical Expression of Cyclin D1 in Invasive Ductal Carcinoma of Human Breast

Assem¹,

Youssef²,

Rashad³

et al. 2017

Oncomedicine

View full text Add to dashboard Cite

Cyclin D1 has been observed in many human tumors and is likely to promote cell proliferation and differentiation by shortening the G1/S transition. This work was aimed to evaluate the prognostic role of Cyclin D1 in invasive ductal carcinoma (IDC) and its correlation with other established prognostic parameters of breast cancer. This study was conducted on 40 prospective biopsies taken from patients with breast tumor; 30 cases having IDC and 10 cases with benign tumor as well as 10 normal biopsies. Sections from all cases were subjected to stain with haematoxylin and eosin (H&E) for histopathological examination and immunohistochemical technique for Cyclin D1 in addition using flow cytometric technique to perform cell cycle analysis. Histopathological results showed fibroadenoma and fibrocystic disease in benign cases and IDC with 60% grade II and 40% grade III in malignant cases. Immunohistochemical results revealed higher expression of Cyclin D1 in IDC comparing to normal and benign breast tissues. Statistically there was significant correlation between Cyclin D1 scores and the positivity of estrogen receptor (ER) and progesterone receptor (PR), and no significant correlation was seen between Cyclin D1 and S-phase %. It could be suggested that Cyclin D1 protein may be a valuable prognostic marker in IDC and can be targeted in the future therapeutic approaches.

show abstract

Section: Methodsmentioning

confidence: 99%

“…All the malignant cases were diagnosed as IDC and graded according to NPI [14]. The grade II (GII) cases were 60% while grade III (GIII) cases presented 40%.…”

Section: Pathological Parametersmentioning

confidence: 99%

Immunohistochemical Expression of Cyclin D1 in Invasive Ductal Carcinoma of Human Breast

Assem¹,

Youssef²,

Rashad³

et al. 2017

Oncomedicine

View full text Add to dashboard Cite

show abstract

“…Clinicopathological risk indexes included: St Gallen guidelines [24][25][26][27][28], Nottingham Prognostic Index [29][30][31], Dutch CBO guidelines 2004-available at www.oncoline.nl- [32,33] and Adjuvant! Online-available at www.adjuvantonline.com [34][35][36].…”

Section: Established Clinical Risk Classifications Indexesmentioning

confidence: 99%

Validation of 70-gene prognosis signature in node-negative breast cancer

Bueno-de-Mesquita

Linn

Keijzer

et al. 2008

Breast Cancer Res Treat

151

View full text Add to dashboard Cite

International audienceThe 70-gene prognosis signature (van't Veer et al., Nature 415(6871):530–536, 2002) may improve the selection of lymph node-negative breast cancer patients for adjuvant systemic therapy. Optimal validation of prognostic classifiers is of great importance and we therefore wished to evaluate the prognostic value of the 70-gene prognosis signature in a series of relatively recently diagnosed lymph node negative breast cancer patients. We evaluated the 70-gene prognosis signature in an independent representative series of patients with invasive breast cancer ( = 123; <55 years; pT1-2N0; diagnosed between 1996 and 1999; median follow-up 5.8 years) by classifying these patients as having a good or poor prognosis signature. In addition, we updated the follow-up of the node-negative patients of the previously published validation-series (Van de Vijver et al., N Engl J Med 347(25):1999–2009, 2002; = 151; median follow-up 10.2 years). The prognostic value of the 70-gene prognosis signature was compared with that of four commonly used clinicopathological risk indexes. The endpoints were distant metastasis (as first event) free percentage (DMFP) and overall survival (OS). The 5-year OS was 82 ± 5% in poor (48%) and 97 ± 2% in good prognosis signature (52%) patients (HR 3.4; 95% CI 1.2–9.6; = 0.021). The 5-years DMFP was 78 ± 6% in poor and 98 ± 2% in good prognosis signature patients (HR 5.7; 95% CI 1.6–20; = 0.007). In the updated series ( = 151; 60% poor vs. 40% good), the 10-year OS was 51 ± 5% and 94 ± 3% (HR 10.7; 95% CI 3.9–30; < 0.01), respectively. The DMFP was 50 ± 6% in poor and 86 ± 5% in good prognosis signature patients (HR 5.5; 95% CI 2.5–12; < 0.01). In multivariate analysis, the prognosis signature was a strong independent prognostic factor in both series, outperforming the clinicopathological risk indexes. The 70-gene prognosis signature is also an independent prognostic factor in node-negative breast cancer patients for women diagnosed in recent years

show abstract

“…As opposed to the British study, the Danish group used conventional axillary lymph-node staging and SBR grade evaluated only in ductal carcinomas (Balslev et al, 1994). Paradoxical data have been published concerning the prognostic significance of the NPI ever since (Sauerbrei et al, 1997;Sundquist et al, 1999;D'Eredita et al, 2001;Malmstrom et al, 2001;Fredriksson et al, 2002). Moreover, the NPI has not been evaluated in a neoadjuvant setting and, as for the SBR grade, we could wonder if it retains its prognostic value after primary chemotherapy.…”

mentioning

confidence: 99%

Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?

et al. 2003

View full text Add to dashboard Cite

The Nottingham prognostic index (NPI), based on tumour size in breast, node involvement and Scarff -Bloom -Richardson (SBR) grading, has been shown to constitute a definitive prognostic factor of primary operable breast cancer in the adjuvant setting. We performed a retrospective study to evaluate the prognostic value of this index in 163 patients after neoadjuvant chemotherapy. Secondly, we examined the influence on survival of a revised NPI, only based on residual tumour size in breast and SBR grading in 228 patients, and consequently called breast grading index (BGI). The prognostic value of these two indices was also evaluated by replacing the SBR grade with the MSBR grade, a French modified SBR grading; the modified NPI (MNPI) and modified BGI (MBGI) were, respectively, obtained in 153 and 222 patients. At a median follow-up of 9.3 years, survival was significantly related to these four indices (Po0.001). Multivariate analysis revealed that MBGI was the only one which retained a prognostic influence on disease-free survival (Po0.02). In conclusion, the 'amount' of residual tumour in breast and/or nodes, as defined by NPI and revised indices, confers a determinant prognosis after neoadjuvant chemotherapy, inviting an alternative postsurgical treatment for a subgroup of patients with a decreased survival.

show abstract

Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution

Cited by 156 publications

References 22 publications

Immunohistochemical Expression of Cyclin D1 in Invasive Ductal Carcinoma of Human Breast

Immunohistochemical Expression of Cyclin D1 in Invasive Ductal Carcinoma of Human Breast

Validation of 70-gene prognosis signature in node-negative breast cancer

Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?

Contact Info

Product

Resources

About